Lichen sclerosus affects an estimated 0.1 to 0.3% of the general population, making it uncommon but far from rare. Because it often goes undiagnosed or gets mistaken for other conditions, the true number of people living with it is almost certainly higher than official figures suggest.
Overall Prevalence Estimates
Population-level data puts the incidence of lichen sclerosus between 1 and 3 in every 1,000 people across both sexes. A U.S. study examining health records between 2015 and 2017 identified just over 10,000 women with a diagnosis, translating to a prevalence of 0.05%, a figure that likely reflects underdiagnosis rather than true rarity. In gynecology practices, where clinicians are more attuned to the condition, prevalence climbs to 1.7%.
Age plays a significant role. Among women over 80 in the general population, prevalence sits around 0.29%. But in nursing home residents over 80, that number jumps to 3%, likely driven by factors like incontinence and reduced mobility that worsen or unmask existing disease.
Who Gets It Most Often
Women are affected far more than men, with estimates ranging from a 3:1 to 10:1 female-to-male ratio. The condition has traditionally been described as having two peak periods of onset: before puberty and after menopause. U.S. data confirms that the postmenopausal years are the most common window. In one large dataset, 53% of diagnosed women were between 55 and 65, another 26% were between 45 and 54, and just 16% were younger adults between 18 and 44. The average age at diagnosis was about 51.
In men, lichen sclerosus primarily affects the foreskin and head of the penis. One U.S. military medical center found an incidence of 0.07% in men, while a broader Department of Defense analysis put it much lower at 0.0014%. The wide gap between these numbers highlights how much detection depends on who’s looking and where.
Children develop lichen sclerosus at an estimated rate of 0.04 to 0.06%. Unlike in adults, the sex ratio in children tilts slightly toward boys (1:1.7 female-to-male). In girls, the average age of onset is around 6.5 years; in boys, it’s closer to 8.6 years. Roughly 1 in 900 premenarchal girls will develop it.
Why the Numbers Are Probably Too Low
Lichen sclerosus is widely considered underdiagnosed. A UK survey of patients with vulvar lichen sclerosus found that one in five had been misdiagnosed before getting the correct answer. The most common wrong diagnosis was a yeast infection. A third of respondents said they felt a lack of knowledge among their healthcare providers delayed their diagnosis, and separate research found that the average gap between first symptoms and a correct diagnosis was three years.
This delay matters because the condition tends to worsen over time without treatment. People who don’t know what they have often cycle through over-the-counter remedies for conditions they don’t actually have, losing years they could have spent managing their symptoms effectively. The gap between the 0.05% prevalence found in insurance records and the 1.7% seen in gynecology clinics strongly suggests that most cases simply aren’t being captured in general medical data.
Autoimmune and Genetic Connections
Between 20 and 30% of women with lichen sclerosus also have at least one autoimmune condition. Thyroid disease is the most common overlap, present in 12 to 16% of affected women. This clustering suggests the immune system plays a central role in driving the disease, and it means people already living with an autoimmune condition may carry higher baseline risk.
Genetics also appear to matter. In a large observational study, 12% of patients with lichen sclerosus had a family member with the same condition. That’s a notably high rate for a disease often considered sporadic, and it points to an inherited component that increases susceptibility.
Long-Term Cancer Risk
One reason prevalence tracking matters is the link between lichen sclerosus and skin cancer in the affected area. Multiple studies of women with long-standing vulvar disease have found a 4 to 5% risk of developing squamous cell carcinoma over time. This risk is one of the main reasons ongoing monitoring is recommended even when symptoms are well controlled. Consistent treatment appears to reduce that risk, which makes early and accurate diagnosis all the more important.
How Common It Looks in Practice
For clinicians who specialize in vulvar conditions, lichen sclerosus is a routine part of their caseload. In a survey of dermatologists and gynecologists working in dedicated vulvar clinics, over half reported seeing more than 10 patients with the condition per month, and nearly a quarter saw more than 25. For a general practitioner who doesn’t focus on this area, though, it may seem rare simply because they encounter it less often and may not recognize it when they do.
This disconnect between specialty clinics and primary care is a core reason the condition remains underdiagnosed. It’s common enough that specialists see it daily, yet unfamiliar enough in general practice that patients frequently wait years for answers.